Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 8:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 22,258 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Immune Clear all
Recruiting Phase 1 Interventional

Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel

NCT05794958
View directory record Official record
Conditions
Non-Hodgkin Lymphoma, Large B-cell Lymphoma
Interventions
Axicabtagene Ciloleucel
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2038
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Sep 9, 2026, 8:02 AM EDT
Terminated No phase listed Observational

Biomarkers in Blood Samples From Patients With HIV Infection and Stage III or Stage IV Hodgkin Lymphoma Undergoing Chemotherapy

NCT01319526
View directory record Official record
Conditions
Lymphoma, Nonneoplastic Condition
Interventions
DNA analysis, RNA analysis, laboratory biomarker analysis
Genetic · Other
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Sep 9, 2026, 8:02 AM EDT
Completed Phase 2 Interventional

Studies of Influenza Vaccine and Tetanus-Pneumococcal Vaccine in HIV-infected Patients Receiving Interleukin-2

NCT00050726
View directory record Official record
Conditions
HIV Infections
Interventions
Interleukin-2
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
620 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 20, 2013 · Synced Sep 9, 2026, 8:02 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors

NCT02440685
View directory record Official record
Conditions
Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Lymphoma, Follicular, Cancer, Neoplasm, Tumor, Lymphoma, Malignant, Lymphoma, B-cell, Lymphoma, Non-Hodgkin, B-Cell Chronic Lymphocytic Leukemia, B-Cell Leukemia, Chronic, B-Lymphocytic Leukemia, Chronic, Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Chronic, Leukemia, Lymphocytic, Chronic, B Cell, Myelofibrosis, Chronic Idiopathic Myelofibrosis, Idiopathic Myelofibrosis, Lymphoma, T Cell, Peripheral, Peripheral T-Cell Lymphoma, T-Cell Lymphoma, Peripheral
Interventions
ASN002 Dose Escalation, ASN002 RD
Drug
Lead sponsor
Asana BioSciences
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
12
States / cities
Tempe, Arizona • San Francisco, California • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2023 · Synced Sep 9, 2026, 8:02 AM EDT
Terminated Phase 1Phase 2 Interventional

Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma

NCT00243035
View directory record Official record
Conditions
Refractory Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions
bortezomib, tipifarnib, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 7, 2013 · Synced Sep 9, 2026, 8:02 AM EDT
Recruiting No phase listed Observational

Collection of Samples and Clinical Data From Patients With Amyloid Diseases

NCT00898235
View directory record Official record
Conditions
Multiple Myeloma
Interventions
clonality analysis, polymerase chain reaction, protein analysis, biologic sample preservation procedure, laboratory biomarker analysis, fluorescence spectroscopy, quality-of-life assessment
Genetic · Other · Procedure
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2040
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 30, 2025 · Synced Sep 9, 2026, 8:02 AM EDT
Not listed Phase 2 Interventional

Bisphosphonate Therapy for HIV-Infected Adults With Decreased Bone Mineral Density

NCT00102908
View directory record Official record
Conditions
HIV Infections, Osteopenia, Osteoporosis
Interventions
Zoledronate, Zoledronate placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2008 · Synced Sep 9, 2026, 8:02 AM EDT
Withdrawn No phase listed Observational

A Pilot Study to Explore the Role of Gut Flora in Rheumatoid Arthritis

NCT04210817
View directory record Official record
Conditions
Rheumatoid Arthritis, Arthritis, Rheumatoid, Arthritis
Interventions
No Intervention
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Sep 9, 2026, 8:02 AM EDT
Recruiting No phase listed Observational

Study of Chediak-Higashi Syndrome

NCT00005917
View directory record Official record
Conditions
Chediak-Higashi Syndrome
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
1 Month to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 9, 2026, 8:02 AM EDT
Completed Phase 2Phase 3 Interventional Results available

A Long Term Safety Study of BCX7353 in Hereditary Angioedema

NCT03472040
View directory record Official record
Conditions
Hereditary Angioedema, HAE, Prophylaxis
Interventions
BCX7353
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
387 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
42
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bentonville, Arkansas + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Sep 9, 2026, 8:02 AM EDT
Recruiting No phase listed Observational

A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting

NCT06794268
View directory record Official record
Conditions
Follicular Lymphoma
Interventions
Lisocabtagene maraleucel
Biological
Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2044
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced Sep 9, 2026, 8:02 AM EDT
Completed Not applicable Interventional

Lakeshore Examination of Activity and Disability Exercise Response Study

NCT02533882
View directory record Official record
Conditions
Multiple Sclerosis, Stroke
Interventions
Movement to Music, Adapted Yoga
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Sep 9, 2026, 8:02 AM EDT
Not listed No phase listed Observational

Mechanisms of Immune Deficiency

NCT03707782
View directory record Official record
Conditions
Immune Deficiency
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 99 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Sep 9, 2026, 8:02 AM EDT
Completed Phase 1 Interventional

Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma

NCT02309580
View directory record Official record
Conditions
T-cell Lymphoma, Relapsed and Refractory T-cell Lymphoma
Interventions
Ibrutinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
2
States / cities
New York, New York • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Sep 9, 2026, 8:02 AM EDT
Completed Phase 2 Interventional Results available

A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.

NCT02612779
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elotuzumab, Pomalidomide, Dexamethasone, Nivolumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
22
States / cities
Mobile, Alabama • Santa Barbara, California • Denver, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2021 · Synced Sep 9, 2026, 8:02 AM EDT
Completed Phase 1 Interventional

A Placebo-Controlled, Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Envelope Proteins of HIV-1 gp160 and gp120 in Children >= 1 Month Old With Asymptomatic HIV Infection

NCT00000762
View directory record Official record
Conditions
HIV Infections
Interventions
rgp120/HIV-1MN, rgp120/HIV-1 SF-2, gp160 Vaccine (MicroGeneSys)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Month to 18 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1996
U.S. locations
33
States / cities
Long Beach, California • Los Angeles, California • Oakland, California + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Sep 9, 2026, 8:02 AM EDT
Suspended Phase 2 Interventional

TOP 2301: Neoadjuvant Chemo for NSCLC

NCT06385262
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Alirocumab, Cemiplimab, Chemotherapy
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 9, 2026, 8:02 AM EDT
Terminated Phase 3 Interventional Results available

Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis

NCT04181762
View directory record Official record
Conditions
Lupus Nephritis
Interventions
secukinumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
8
States / cities
Birmingham, Alabama • Fontana, California • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Sep 9, 2026, 8:02 AM EDT
Completed Not applicable Interventional Results available

Vitamin D Absorption in HIV Infected Young Adults Being Treated With Tenofovir Containing cART

NCT01751646
View directory record Official record
Conditions
HIV Infection
Interventions
Vitamin D3 50,000 IU, Vitamin D3 placebo
Dietary Supplement
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 24 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
16
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Sep 9, 2026, 8:02 AM EDT
Completed Phase 2 Interventional Results available

Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia

NCT00759603
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Lenalidomide, Rituximab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 26, 2015 · Synced Sep 9, 2026, 8:02 AM EDT
Active, not recruiting No phase listed Observational

Brigham and Women's Rheumatoid Arthritis Sequential Study

NCT01793103
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
1,598 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Sep 9, 2026, 8:02 AM EDT
Completed Phase 1 Interventional

Safety of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy

NCT01170286
View directory record Official record
Conditions
Peanut Allergy
Interventions
Whole peanut extract, Placebo formulation
Biological
Lead sponsor
DBV Technologies
Industry
Eligibility
6 Years to 50 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
Little Rock, Arkansas • Denver, Colorado • Willingboro, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2012 · Synced Sep 9, 2026, 8:02 AM EDT
Completed Not applicable Interventional

RAHelp.Org: An Online Self Management Program for Adults With Rheumatoid Arthritis

NCT00283855
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Online Self-Management
Behavioral
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 29, 2016 · Synced Sep 9, 2026, 8:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving HIV Screening With Nurse-Based Rapid Testing/Streamlined Counseling

NCT00119548
View directory record Official record
Conditions
Health Care Quality, Access, and Evaluation, Delivery of Health Care, Immune System Diseases, HIV Infections
Interventions
Rates of HIV testing and receipt of results, Sexual risk reduction; HIV knowledge improvement
Other
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 65 Years
Enrollment
251 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
West Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Sep 9, 2026, 8:02 AM EDT